vs
ANI PHARMACEUTICALS INC（ANIP）与OneStream, Inc.（OS）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是OneStream, Inc.的1.5倍（$247.1M vs $163.7M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 0.6%，领先10.5%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 23.6%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $25.6M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 21.8%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Blue Stream面向美国佛罗里达州科勒尔斯普林斯、韦斯顿两地的居民及商业客户，提供有线电视、有线固话、数字录像服务，以及最高速率达1G的宽带互联网接入服务，深耕当地通信市场，为用户提供稳定可靠的多元通信解决方案。
ANIP vs OS — 直观对比
营收规模更大
ANIP
是对方的1.5倍
$163.7M
营收增速更快
ANIP
高出6.0%
23.6%
净利率更高
ANIP
高出10.5%
0.6%
自由现金流更多
ANIP
多$3.5M
$25.6M
两年增速更快
ANIP
近两年复合增速
21.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $163.7M |
| 净利润 | $27.5M | $999.0K |
| 毛利率 | — | 69.8% |
| 营业利润率 | 14.1% | -3.2% |
| 净利率 | 11.1% | 0.6% |
| 营收同比 | 29.6% | 23.6% |
| 净利润同比 | 367.5% | — |
| 每股收益（稀释后） | $1.14 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPOS
| Q4 25 | $247.1M | $163.7M | ||
| Q3 25 | $227.8M | $154.3M | ||
| Q2 25 | $211.4M | $147.6M | ||
| Q1 25 | $197.1M | $136.3M | ||
| Q4 24 | $190.6M | $132.5M | ||
| Q3 24 | $148.3M | $129.1M | ||
| Q2 24 | $138.0M | $117.5M | ||
| Q1 24 | $137.4M | $110.3M |
净利润ANIPOS
| Q4 25 | $27.5M | $999.0K | ||
| Q3 25 | $26.6M | $-8.8M | ||
| Q2 25 | $8.5M | $-18.4M | ||
| Q1 25 | $15.7M | $-24.0M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $-171.9M | ||
| Q2 24 | $-2.3M | $-7.8M | ||
| Q1 24 | $18.2M | $-5.0M |
毛利率ANIPOS
| Q4 25 | — | 69.8% | ||
| Q3 25 | — | 68.1% | ||
| Q2 25 | — | 68.6% | ||
| Q1 25 | — | 68.0% | ||
| Q4 24 | — | 66.8% | ||
| Q3 24 | — | 50.1% | ||
| Q2 24 | — | 68.5% | ||
| Q1 24 | — | 69.1% |
营业利润率ANIPOS
| Q4 25 | 14.1% | -3.2% | ||
| Q3 25 | 15.9% | -11.3% | ||
| Q2 25 | 6.6% | -21.8% | ||
| Q1 25 | 13.3% | -29.3% | ||
| Q4 24 | -2.3% | -35.8% | ||
| Q3 24 | -13.8% | -197.6% | ||
| Q2 24 | 3.7% | -9.8% | ||
| Q1 24 | 14.8% | -4.9% |
净利率ANIPOS
| Q4 25 | 11.1% | 0.6% | ||
| Q3 25 | 11.7% | -5.7% | ||
| Q2 25 | 4.0% | -12.5% | ||
| Q1 25 | 8.0% | -17.6% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | -133.1% | ||
| Q2 24 | -1.7% | -6.7% | ||
| Q1 24 | 13.2% | -4.5% |
每股收益（稀释后）ANIPOS
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | $-1.06 | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $0.82 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $693.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $504.7M |
| 总资产 | $1.4B | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPOS
| Q4 25 | $285.6M | $693.6M | ||
| Q3 25 | $262.6M | $653.9M | ||
| Q2 25 | $217.8M | $652.1M | ||
| Q1 25 | $149.8M | $593.9M | ||
| Q4 24 | $144.9M | $544.2M | ||
| Q3 24 | $145.0M | $495.5M | ||
| Q2 24 | $240.1M | $140.5M | ||
| Q1 24 | $228.6M | — |
股东权益ANIPOS
| Q4 25 | $540.7M | $504.7M | ||
| Q3 25 | $505.8M | $472.1M | ||
| Q2 25 | $436.8M | $458.2M | ||
| Q1 25 | $418.6M | $412.9M | ||
| Q4 24 | $403.7M | $386.2M | ||
| Q3 24 | $405.9M | $458.2M | ||
| Q2 24 | $455.8M | $97.5M | ||
| Q1 24 | $452.0M | $102.5M |
总资产ANIPOS
| Q4 25 | $1.4B | $1.0B | ||
| Q3 25 | $1.4B | $949.4M | ||
| Q2 25 | $1.3B | $910.5M | ||
| Q1 25 | $1.3B | $867.3M | ||
| Q4 24 | $1.3B | $823.2M | ||
| Q3 24 | $1.3B | $750.1M | ||
| Q2 24 | $920.8M | $379.7M | ||
| Q1 24 | $914.5M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $25.8M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $25.6M |
| 自由现金流率自由现金流/营收 | 11.8% | 15.7% |
| 资本支出强度资本支出/营收 | 0.5% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.10× | 25.79× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $95.6M |
8季度趋势，按日历期对齐
经营现金流ANIPOS
| Q4 25 | $30.4M | $25.8M | ||
| Q3 25 | $44.1M | $5.0M | ||
| Q2 25 | $75.8M | $29.7M | ||
| Q1 25 | $35.0M | $36.2M | ||
| Q4 24 | $15.9M | — | ||
| Q3 24 | $12.5M | $2.4M | ||
| Q2 24 | $17.4M | $8.1M | ||
| Q1 24 | $18.3M | $25.5M |
自由现金流ANIPOS
| Q4 25 | $29.1M | $25.6M | ||
| Q3 25 | $38.0M | $4.8M | ||
| Q2 25 | $71.8M | $29.4M | ||
| Q1 25 | $32.5M | $35.8M | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | $1.3M | ||
| Q2 24 | $13.0M | $7.7M | ||
| Q1 24 | $13.7M | $24.9M |
自由现金流率ANIPOS
| Q4 25 | 11.8% | 15.7% | ||
| Q3 25 | 16.7% | 3.1% | ||
| Q2 25 | 34.0% | 19.9% | ||
| Q1 25 | 16.5% | 26.3% | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | 1.0% | ||
| Q2 24 | 9.4% | 6.6% | ||
| Q1 24 | 10.0% | 22.5% |
资本支出强度ANIPOS
| Q4 25 | 0.5% | 0.1% | ||
| Q3 25 | 2.7% | 0.1% | ||
| Q2 25 | 1.9% | 0.2% | ||
| Q1 25 | 1.3% | 0.3% | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | 0.8% | ||
| Q2 24 | 3.2% | 0.3% | ||
| Q1 24 | 3.3% | 0.6% |
现金转化率ANIPOS
| Q4 25 | 1.10× | 25.79× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
OS
| Subscription And Circulation | $150.3M | 92% |
| Professional Services And Other | $9.4M | 6% |
| License | $4.0M | 2% |
